Search

Your search keyword '"Chiarion-Sileni, Vanna"' showing total 724 results
Start Over Author "Chiarion-Sileni, Vanna"
724 results on '"Chiarion-Sileni, Vanna"'

202. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials

Author

Schadendorf, Dirk, primary, Wolchok, Jedd D., additional, Hodi, F. Stephen, additional, Chiarion-Sileni, Vanna, additional, Gonzalez, Rene, additional, Rutkowski, Piotr, additional, Grob, Jean-Jacques, additional, Cowey, C. Lance, additional, Lao, Christopher D., additional, Chesney, Jason, additional, Robert, Caroline, additional, Grossmann, Kenneth, additional, McDermott, David, additional, Walker, Dana, additional, Bhore, Rafia, additional, Larkin, James, additional, and Postow, Michael A., additional

Published
2017
Full Text
View/download PDF

203. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma:a randomised, double-blind, multicentre, phase 3 trial

Author

Ascierto, Paolo A, Del Vecchio, Michele, Robert, Caroline, Mackiewicz, Andrzej, Chiarion-Sileni, Vanna, Arance, Ana, Lebbé, Céleste, Bastholt, Lars, Hamid, Omid, Rutkowski, Piotr, McNeil, Catriona, Garbe, Claus, Loquai, Carmen, Dreno, Brigitte, Thomas, Luc, Grob, Jean-Jacques, Liszkay, Gabriella, Nyakas, Marta, Gutzmer, Ralf, Pikiel, Joanna, Grange, Florent, Hoeller, Christoph, Ferraresi, Virginia, Smylie, Michael, Schadendorf, Dirk, Mortier, Laurent, Svane, Inge Marie, Hennicken, Delphine, Qureshi, Anila, Maio, Michele, Ascierto, Paolo A, Del Vecchio, Michele, Robert, Caroline, Mackiewicz, Andrzej, Chiarion-Sileni, Vanna, Arance, Ana, Lebbé, Céleste, Bastholt, Lars, Hamid, Omid, Rutkowski, Piotr, McNeil, Catriona, Garbe, Claus, Loquai, Carmen, Dreno, Brigitte, Thomas, Luc, Grob, Jean-Jacques, Liszkay, Gabriella, Nyakas, Marta, Gutzmer, Ralf, Pikiel, Joanna, Grange, Florent, Hoeller, Christoph, Ferraresi, Virginia, Smylie, Michael, Schadendorf, Dirk, Mortier, Laurent, Svane, Inge Marie, Hennicken, Delphine, Qureshi, Anila, and Maio, Michele

Abstract

BACKGROUND: A phase 2 trial suggested increased overall survival and increased incidence of treatment-related grade 3-4 adverse events with ipilimumab 10 mg/kg compared with ipilimumab 3 mg/kg in patients with advanced melanoma. We report a phase 3 trial comparing the benefit-risk profile of ipilimumab 10 mg/kg versus 3 mg/kg.METHODS: This randomised, double-blind, multicentre, phase 3 trial was done in 87 centres in 21 countries worldwide. Patients with untreated or previously treated unresectable stage III or IV melanoma, without previous treatment with BRAF inhibitors or immune checkpoint inhibitors, were randomly assigned (1:1) with an interactive voice response system by the permuted block method using block size 4 to ipilimumab 10 mg/kg or 3 mg/kg, administered by intravenous infusion for 90 min every 3 weeks for four doses. Patients were stratified by metastasis stage, previous treatment for metastatic melanoma, and Eastern Cooperative Oncology Group performance status. The patients, investigators, and site staff were masked to treatment assignment. The primary endpoint was overall survival in the intention-to-treat population and safety was assessed in all patients who received at least one dose of study treatment. This study is completed and was registered with ClinicalTrials.gov, number NCT01515189.FINDINGS: Between Feb 29, and July 9, 2012, 727 patients were enrolled and randomly assigned to ipilimumab 10 mg/kg (365 patients; 364 treated) or ipilimumab 3 mg/kg (362 patients; all treated). Median follow-up was 14·5 months (IQR 4·6-42·3) for the ipilimumab 10 mg/kg group and 11·2 months (4·9-29·4) for the ipilimumab 3 mg/kg group. Median overall survival was 15·7 months (95% CI 11·6-17·8) for ipilimumab 10 mg/kg compared with 11·5 months (9·9-13·3) for ipilimumab 3 mg/kg (hazard ratio 0·84, 95% CI 0·70-0·99; p=0·04). The most common grade 3-4 treatment-related adverse events were diarrhoea (37 [10%] of 364 patients in the 10 mg/kg group vs

Published
2017

204. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

Author

Long, Georgina V, Hauschild, Axel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Schadendorf, Dirk, Lesimple, Thierry, Plummer, Ruth, Ji, Ran, Zhang, Pingkuan, Mookerjee, Bijoyesh, Legos, Jeff, Kefford, Richard, Dummer, Reinhard, Kirkwood, John M, Long, Georgina V, Hauschild, Axel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Schadendorf, Dirk, Lesimple, Thierry, Plummer, Ruth, Ji, Ran, Zhang, Pingkuan, Mookerjee, Bijoyesh, Legos, Jeff, Kefford, Richard, Dummer, Reinhard, and Kirkwood, John M

Published
2017

205. Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma

Author

Long, Georgina V., primary, Hauschild, Axel, additional, Santinami, Mario, additional, Atkinson, Victoria, additional, Mandalà, Mario, additional, Chiarion-Sileni, Vanna, additional, Larkin, James, additional, Nyakas, Marta, additional, Dutriaux, Caroline, additional, Haydon, Andrew, additional, Robert, Caroline, additional, Mortier, Laurent, additional, Schachter, Jacob, additional, Schadendorf, Dirk, additional, Lesimple, Thierry, additional, Plummer, Ruth, additional, Ji, Ran, additional, Zhang, Pingkuan, additional, Mookerjee, Bijoyesh, additional, Legos, Jeff, additional, Kefford, Richard, additional, Dummer, Reinhard, additional, and Kirkwood, John M., additional

Published
2017
Full Text
View/download PDF

207. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis

Author

Blank, Christian U., primary, Larkin, James, additional, Arance, Ana M., additional, Hauschild, Axel, additional, Queirolo, Paola, additional, Del Vecchio, Michele, additional, Ascierto, Paolo A., additional, Krajsova, Ivana, additional, Schachter, Jacob, additional, Neyns, Bart, additional, Garbe, Claus, additional, Chiarion Sileni, Vanna, additional, Mandalà, Mario, additional, Gogas, Helen, additional, Espinosa, Enrique, additional, Hospers, Geke A.P., additional, Miller, Wilson H., additional, Robson, Susan, additional, Makrutzki, Martina, additional, Antic, Vladan, additional, and Brown, Michael P., additional

Published
2017
Full Text
View/download PDF

208. Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067)

Author

Larkin, James, primary, Chiarion-Sileni, Vanna, additional, Gonzalez, Rene, additional, Rutkowski, Piotr, additional, Grob, Jean-Jacques, additional, Cowey, C. Lance, additional, Lao, Christopher D., additional, Schadendorf, Dirk, additional, Ferrucci, Pier Francesco, additional, Smylie, Michael, additional, Dummer, Reinhard, additional, Hill, Andrew, additional, Haanen, John, additional, Maio, Michele, additional, McArthur, Grant, additional, Walker, Dana, additional, Rollin, Linda, additional, Horak, Christine, additional, Hodi, F. Stephen, additional, and Wolchok, Jedd D., additional

Published
2017
Full Text
View/download PDF

209. COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant (mut) melanoma brain metastases (MBM).

Author

Davies, Michael A., primary, Robert, Caroline, additional, Long, Georgina V., additional, Grob, Jean Jacques, additional, Flaherty, Keith T., additional, Arance, Ana, additional, Chiarion-Sileni, Vanna, additional, Thomas, Luc, additional, Lesimple, Thierry, additional, Mortier, Laurent, additional, Moschos, Stergios J., additional, Hogg, David, additional, Marquez Rodas, Ivan, additional, Del Vecchio, Michele, additional, Lebbe, Celeste, additional, Meyer, Nicolas, additional, Zhang, Ying, additional, Huang, Yingjie, additional, Mookerjee, Bijoyesh, additional, and Saiag, Philippe, additional

Published
2017
Full Text
View/download PDF

210. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Author

Segal, Neil H., primary, Logan, Theodore F., additional, Hodi, F. Stephen, additional, McDermott, David, additional, Melero, Ignacio, additional, Hamid, Omid, additional, Schmidt, Henrik, additional, Robert, Caroline, additional, Chiarion-Sileni, Vanna, additional, Ascierto, Paolo A., additional, Maio, Michele, additional, Urba, Walter J., additional, Gangadhar, Tara C., additional, Suryawanshi, Satyendra, additional, Neely, Jaclyn, additional, Jure-Kunkel, Maria, additional, Krishnan, Suba, additional, Kohrt, Holbrook, additional, Sznol, Mario, additional, and Levy, Ronald, additional

Published
2017
Full Text
View/download PDF

214. Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma

Author

Long, Georgina V. Stroyakovskiy, Daniil Gogas, Helen and Levchenko, Evgeny De Braud, Filippo G. Larkin, James M. G. and Garbe, Claus Jouary, Thomas Hauschild, Axel Grob, Jean Jacques Chiarion-Sileni, Vanna Lebbe, Celeste Mandala, Mario and Millward, Michael DeMarini, Douglas James Irani, Jhangir G. and Jin, Fan Swann, R. Suzanne Mookerjee, Bijoyesh Flaherty, Keith

Published
2015

215. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected V600-Mutant Stage III Melanoma.

Author

Hauschild, Axel, Dummer, Reinhard, Schadendorf, Dirk, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Chiarion-Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Lesimple, Thierry, Plummer, Ruth, Dasgupta, Kohinoor, Haas, Tomas, Shilkrut, Mark, and Gasal, Eduard

Published
2018
Full Text
View/download PDF

217. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy

Author

Eggermont, Alexander M M, Chiarion-Sileni, Vanna, Grob, Jean-Jacques, Dummer, Reinhard, Wolchok, Jedd D, Schmidt, Henrik, Hamid, Omid, Robert, Caroline, Ascierto, Paolo A, Richards, Jon M, Lebbé, Céleste, Ferraresi, Virginia, Smylie, Michael, Weber, Jeffrey S, Maio, Michele, Bastholt, Lars, Mortier, Laurent, Thomas, Luc, Tahir, Saad, Hauschild, Axel, Hassel, Jessica C, Hodi, F Stephen, Taitt, Corina, de Pril, Veerle, de Schaetzen, Gaetan, Suciu, Stefan, Testori, Alessandro, Eggermont, Alexander M M, Chiarion-Sileni, Vanna, Grob, Jean-Jacques, Dummer, Reinhard, Wolchok, Jedd D, Schmidt, Henrik, Hamid, Omid, Robert, Caroline, Ascierto, Paolo A, Richards, Jon M, Lebbé, Céleste, Ferraresi, Virginia, Smylie, Michael, Weber, Jeffrey S, Maio, Michele, Bastholt, Lars, Mortier, Laurent, Thomas, Luc, Tahir, Saad, Hauschild, Axel, Hassel, Jessica C, Hodi, F Stephen, Taitt, Corina, de Pril, Veerle, de Schaetzen, Gaetan, Suciu, Stefan, and Testori, Alessandro

Abstract

Background On the basis of data from a phase 2 trial that compared the checkpoint inhibitor ipilimumab at doses of 0.3 mg, 3 mg, and 10 mg per kilogram of body weight in patients with advanced melanoma, this phase 3 trial evaluated ipilimumab at a dose of 10 mg per kilogram in patients who had undergone complete resection of stage III melanoma. Methods After patients had undergone complete resection of stage III cutaneous melanoma, we randomly assigned them to receive ipilimumab at a dose of 10 mg per kilogram (475 patients) or placebo (476) every 3 weeks for four doses, then every 3 months for up to 3 years or until disease recurrence or an unacceptable level of toxic effects occurred. Recurrence-free survival was the primary end point. Secondary end points included overall survival, distant metastasis-free survival, and safety. Results At a median follow-up of 5.3 years, the 5-year rate of recurrence-free survival was 40.8% in the ipilimumab group, as compared with 30.3% in the placebo group (hazard ratio for recurrence or death, 0.76; 95% confidence interval [CI], 0.64 to 0.89; P<0.001). The rate of overall survival at 5 years was 65.4% in the ipilimumab group, as compared with 54.4% in the placebo group (hazard ratio for death, 0.72; 95.1% CI, 0.58 to 0.88; P=0.001). The rate of distant metastasis-free survival at 5 years was 48.3% in the ipilimumab group, as compared with 38.9% in the placebo group (hazard ratio for death or distant metastasis, 0.76; 95.8% CI, 0.64 to 0.92; P=0.002). Adverse events of grade 3 or 4 occurred in 54.1% of the patients in the ipilimumab group and in 26.2% of those in the placebo group. Immune-related adverse events of grade 3 or 4 occurred in 41.6% of the patients in the ipilimumab group and in 2.7% of those in the placebo group. In the ipilimumab group, 5 patients (1.1%) died owing to immune-related adverse events. Conclusions As adjuvant therapy for high-risk stage III melanoma, ipilimumab at a dose of 10 mg per kilogram resulted

Published
2016

218. COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF(V600E/K) mutation-positive cutaneous melanoma

Author

Long, Georgina V. Stroyakovsky, Daniil L. Gogas, Helen and Levchenko, Eugeny de Braud, Filippo Larkin, James M. G. and Garbe, Claus Jouary, Thomas Hauschild, Axel Grob, Jean Jacques Chiarion-Sileni, Vanna Lebbe, Celeste Mandala, Mario and Millward, Michael DeMarini, Douglas James Irani, Jhangir G. and Le, Ngocdiep Casey, Michelle Patel, Kiran Flaherty, Keith

Published
2014

219. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

Author

Eggermont, Alexander M.M., primary, Chiarion-Sileni, Vanna, additional, Grob, Jean-Jacques, additional, Dummer, Reinhard, additional, Wolchok, Jedd D., additional, Schmidt, Henrik, additional, Hamid, Omid, additional, Robert, Caroline, additional, Ascierto, Paolo A., additional, Richards, Jon M., additional, Lebbé, Céleste, additional, Ferraresi, Virginia, additional, Smylie, Michael, additional, Weber, Jeffrey S., additional, Maio, Michele, additional, Bastholt, Lars, additional, Mortier, Laurent, additional, Thomas, Luc, additional, Tahir, Saad, additional, Hauschild, Axel, additional, Hassel, Jessica C., additional, Hodi, F. Stephen, additional, Taitt, Corina, additional, de Pril, Veerle, additional, de Schaetzen, Gaetan, additional, Suciu, Stefan, additional, and Testori, Alessandro, additional

Published
2016
Full Text
View/download PDF

221. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).

Author

Wolchok, Jedd D., primary, Chiarion-Sileni, Vanna, additional, Gonzalez, Rene, additional, Rutkowski, Piotr, additional, Grob, Jean Jacques, additional, Cowey, C. Lance, additional, Lao, Christopher, additional, Schadendorf, Dirk, additional, Ferrucci, Pier Francesco, additional, Smylie, Michael, additional, Dummer, Reinhard, additional, Hill, Andrew, additional, Haanen, John B. A. G., additional, Maio, Michele, additional, McArthur, Grant A., additional, Walker, Dana, additional, Jiang, Joel, additional, Horak, Christine E., additional, Larkin, James M. G., additional, and Hodi, F. Stephen, additional

Published
2016
Full Text
View/download PDF

222. Tu1270 High Levels of CD4+ T Cell Is Associated to Recurrence/Relapse After Clinical Complete Response After Neoadjuvant Chemoradiotherapy for Squamous Cell Cancer of the Thoracic Oesophagus

Author

Scarpa, Marco, primary, Fassan, Matteo, additional, Guzzardo, Vincenza, additional, Kotsafti, Andromachi, additional, Cavallin, Francesco, additional, Alfieri, Rita, additional, Cagol, Matteo, additional, Scarpa, Melania, additional, Chiarion-Sileni, Vanna, additional, Castagliuolo, Ignazio, additional, Rugge, Massimo, additional, and Castoro, Carlo, additional

Published
2016
Full Text
View/download PDF

223. Melanoma M (Zero): Diagnosis and Therapy

Author

Rastrelli, Marco, Alaibac, Mauro, Stramare, Roberto, Chiarion Sileni, Vanna, Montesco, Maria Cristina, Vecchiato, Antonella, Campana, Luca Giovanni, and Rossi, Carlo Riccardo

Subjects
Article Subject
Abstract

This paper reviews the epidemiology, diagnosis, and treatment of M zero cutaneous melanoma including the most recent developments. This review also examined the main risk factors for melanoma. Tumor thickness measured according to Breslow, mitotic rate, ulceration, and growth phase has the greatest predictive value for survival and metastasis. Wide excision of the primary tumor is the only potentially curative treatment for primary melanoma. The sentinel node biopsy must be performed on all patients who have a primary melanoma with a Breslow thickness > 1 mm, or if the melanoma is from 0,75 mm to 1 mm thick but it is ulcerated and/or the mitotic index is ≥1. Total lymph node dissection consists in removing the residual lymph nodes in patients with positive sentinel node biopsy, or found positive on needle aspiration biopsy, without radiological evidence of spread. Isolated limb perfusion and isolated limb infusion are employed in patients within transit metastases with a rate of complete remission in around 50% and 38% of cases. Electrochemotherapy is mainly indicated for palliation in cases of metastatic disease, though it may sometimes be useful to complete isolated limb perfusion. The only agent found to affect survival as an adjuvant treatment is interferon alpha-2. Adjuvant radiotherapy improves local control of melanoma in patients at a high risk of recurrence after lymph node dissection.

Published
2013
Full Text
View/download PDF

224. Effectiveness of dabrafenib in the treatment of patients with BRAFV600–mutated metastatic melanoma in a Named Patient Program

Author

Martin-Algarra, Salvador, Hinshelwood, Rebecca, Mesnage, Soizick, Cebon, Jonathan, Ferrucci, Pier Francesco, Aglietta, Massimo, Neyns, Bart, Chiarion-Sileni, Vanna, Lindsay, Colin R., Del Vecchio, Michele, Linardou, Helen, Merelli, Barbara, Tonini, Giuseppe, Atkinson, Victoria, Freivogel, Klaus, Stein, Dara, Dalland, Lindi, Lau, Mike, Legenne, Philippe, Queirolo, Paola, and Millward, Michael

Abstract

Supplemental Digital Content is available in the text.Given the approval of dabrafenib in patients with BRAF-mutant metastatic melanoma, a better understanding of treatment patterns and clinical outcomes with dabrafenib in a clinical setting is warranted. We performed a retrospective chart review of patients who received dabrafenib in a compassionate use setting through the Named Patient Program (DESCRIBE I study) during December 2010–August 2013 in Europe, New Zealand and Australia. Of the 331 Named Patient Program patients included, the majority (95.8%) had stage IV disease at dabrafenib initiation and 39.9% had brain metastases (BMs). Dabrafenib was used first line in 67.7% of patients, and median treatment duration was 6.4 months. Dabrafenib was well tolerated. Common grade 2/3 adverse events were hyperkeratosis (7.6%), pyrexia/fever (6.6%), fatigue (5.1%), hand-foot syndrome (5.4%) and nausea (3.6%). Overall response rate was 45.9%, median progression-free survival was 5.2 months (95% confidence interval, 4.2–6.1 months), and median overall survival was 12.4 months (95% confidence interval, 10.2–15.0 months). In patients with known brain metastases (n= 132) versus patients without (n= 199), overall response rate was 42.4% versus 48.2%, progression-free survival was 3.9 months (95% confidence interval, 3.8–5.5 months) versus 5.9 months (95% confidence interval, 4.8–7.8 months) and overall survival was 9.5 months (95% confidence interval, 6.7–12.4 months) versus 15 months (95% confidence interval, 11.1–20.5 months), respectively. Safety and effectiveness of dabrafenib in patients with unresectable advanced BRAFV600–mutant melanoma treated in an Named Patient Program was similar to the clinical trial experience, demonstrating effectiveness of dabrafenib in a nontrial setting.

Published
2019
Full Text
View/download PDF

225. Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells

Author

Scaini, Maria Chiara, Pigozzo, Jacopo, Pizzi, Marco, Manicone, Mariangela, Chiarion-Sileni, Vanna, Zambenedetti, Pamela, Rugge, Massimo, Zanovello, Paola, Rossi, Elisabetta, Zamarchi, Rita, and Facchinetti, Antonella

Abstract

Supplemental Digital Content is available in the text.The management of metastatic melanoma is a difficult matter. Nevertheless, the advent of target therapy has significantly improved patient outcome, provided that tumor molecular characteristics become available: the detection of drug-resistant clones can contribute to understanding the reasons for resistance onset, influencing the choice of subsequent therapy. This work aimed to provide a possible explanation for the early resistance to vemurafenib developed by a patient with melanoma, and concurrently to assess the extent, and role, of the tumor clonal heterogeneity. We analyzed tissue samples from different sites and time points: first/second primary, three lymph node metastases, and circulating melanoma cells (CMCs). We first investigated these samples by the routine Sanger sequencing for BRAF, NRAS, and KIT, and then, we focused on specific hotspots by droplet digital PCR. We detected a BRAF V600E mutation by Sanger sequencing in the second primary and distant lymph node metastases, but not in the first primary or sentinel lymph node. Interestingly, by droplet digital PCR, the V600E mutation was also detected in the first primary, and the V600K in the second primary and metastases. Moreover, we identified a rare KIT V569G mutation, appearing to be CMC exclusive. This finding confirms the potential of CMCs as a source of tumor material for genetic analysis, reflecting real-time systemic disease evolution and, most likely, the most aggressive, treatment-resistant clones. In summary, this work underlines the importance of CMCs in the early identification of tumor clones putatively responsible for therapy resistance.

Published
2019
Full Text
View/download PDF

226. Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.

Author

Luke, Jason J., Ascierto, Paolo Antonio, Khattak, Muhammad Adnan, de la Cruz Merino, Luis, Del Vecchio, Michele, Rutkowski, Piotr, Spagnolo, Francesco, Mackiewicz, Jacek, Chiarion-Sileni, Vanna, Kirkwood, John M. M., Robert, Caroline, Grob, Jean-Jacques, de Galitiis, Federica, Schadendorf, Dirk, Carlino, Matteo S., Wu, Larry, Fukunaga-Kalabis, Mizuho, Krepler, Clemens, Eggermont, Alexander M., and Long, Georgina V.

Published
2023
Full Text
View/download PDF

227. NEO-CESQ study: Neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III/IV (M0) cutaneous squamous cell carcinoma.

Author

Ascierto, Paolo Antonio, Bossi, Paolo, Mandalà, Mario, Queirolo, Paola, Spagnolo, Francesco, Bassetto, Franco, Rampinelli, Vittorio, Giovacchini, Francesco, Pennacchioli, Elisabetta, Caraco, Corrado, Parrinello, Gianpiero, Mallardo, Domenico, Giannarelli, Diana, Trojaniello, Claudia, Massi, Daniela, and Chiarion-Sileni, Vanna

Published
2023
Full Text
View/download PDF

228. Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067.

Author

Hodi, F. Stephen, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean-Jacques, Rutkowski, Piotr, Lao, Christopher D., Cowey, Charles Lance, Schadendorf, Dirk, Wagstaff, John, Dummer, Reinhard, Queirolo, Paola, Smylie, Michael, Butler, Marcus O., Hill, Andrew Graham, Marquez-Rodas, Ivan, Ritchings, Corey, Sakkal, Leon A., Wang, Peter, Wolchok, Jedd D., and Larkin, James

Published
2023
Full Text
View/download PDF

229. Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).

Author

Long, Georgina V., Kirkwood, John M. M., Hoeller, Christoph, Grob, Jean-Jacques, Weber, Jeffrey S., Taube, Janis M., Mohr, Peter, Van Akkooi, Alexander Christopher Jonathan, Loquai, Carmen, Dutriaux, Caroline, Chiarion-Sileni, Vanna, Tenney, Daniel J., Dolfi, Sonia, Tang, Hao, Ritchings, Corey, Lobo, Maurice, Campigotto, Federico, Wang, Wenjia, Gastman, Brian, and Del Vecchio, Michele

Published
2023
Full Text
View/download PDF

231. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial

Author

Grob, Jean Jacques, primary, Amonkar, Mayur M, additional, Karaszewska, Boguslawa, additional, Schachter, Jacob, additional, Dummer, Reinhard, additional, Mackiewicz, Andrzej, additional, Stroyakovskiy, Daniil, additional, Drucis, Kamil, additional, Grange, Florent, additional, Chiarion-Sileni, Vanna, additional, Rutkowski, Piotr, additional, Lichinitser, Mikhail, additional, Levchenko, Evgeny, additional, Wolter, Pascal, additional, Hauschild, Axel, additional, Long, Georgina V, additional, Nathan, Paul, additional, Ribas, Antoni, additional, Flaherty, Keith, additional, Sun, Peng, additional, Legos, Jeffrey J, additional, McDowell, Diane Opatt, additional, Mookerjee, Bijoyesh, additional, Schadendorf, Dirk, additional, and Robert, Caroline, additional

Published
2015
Full Text
View/download PDF

232. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Author

Long, Georgina V, primary, Stroyakovskiy, Daniil, additional, Gogas, Helen, additional, Levchenko, Evgeny, additional, de Braud, Filippo, additional, Larkin, James, additional, Garbe, Claus, additional, Jouary, Thomas, additional, Hauschild, Axel, additional, Grob, Jean-Jacques, additional, Chiarion-Sileni, Vanna, additional, Lebbe, Celeste, additional, Mandalà, Mario, additional, Millward, Michael, additional, Arance, Ana, additional, Bondarenko, Igor, additional, Haanen, John B A G, additional, Hansson, Johan, additional, Utikal, Jochen, additional, Ferraresi, Virginia, additional, Kovalenko, Nadezhda, additional, Mohr, Peter, additional, Probachai, Volodymr, additional, Schadendorf, Dirk, additional, Nathan, Paul, additional, Robert, Caroline, additional, Ribas, Antoni, additional, DeMarini, Douglas J, additional, Irani, Jhangir G, additional, Swann, Suzanne, additional, Legos, Jeffrey J, additional, Jin, Fan, additional, Mookerjee, Bijoyesh, additional, and Flaherty, Keith, additional

Published
2015
Full Text
View/download PDF

233. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Author

Larkin, James, primary, Chiarion-Sileni, Vanna, additional, Gonzalez, Rene, additional, Grob, Jean Jacques, additional, Cowey, C. Lance, additional, Lao, Christopher D., additional, Schadendorf, Dirk, additional, Dummer, Reinhard, additional, Smylie, Michael, additional, Rutkowski, Piotr, additional, Ferrucci, Pier F., additional, Hill, Andrew, additional, Wagstaff, John, additional, Carlino, Matteo S., additional, Haanen, John B., additional, Maio, Michele, additional, Marquez-Rodas, Ivan, additional, McArthur, Grant A., additional, Ascierto, Paolo A., additional, Long, Georgina V., additional, Callahan, Margaret K., additional, Postow, Michael A., additional, Grossmann, Kenneth, additional, Sznol, Mario, additional, Dreno, Brigitte, additional, Bastholt, Lars, additional, Yang, Arvin, additional, Rollin, Linda M., additional, Horak, Christine, additional, Hodi, F. Stephen, additional, and Wolchok, Jedd D., additional

Published
2015
Full Text
View/download PDF

234. Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).

Author

Wolchok, Jedd D., primary, Chiarion-Sileni, Vanna, additional, Gonzalez, Rene, additional, Rutkowski, Piotr, additional, Grob, Jean Jacques, additional, Cowey, Charles Lance, additional, Lao, Christopher D., additional, Schadendorf, Dirk, additional, Ferrucci, Pier Francesco, additional, Smylie, Michael, additional, Dummer, Reinhard, additional, Hill, Andrew Graham, additional, Haanen, John B. A. G., additional, Maio, Michele, additional, McArthur, Grant A., additional, Yang, Arvin, additional, Rollin, Linda, additional, Horak, Christine E., additional, Larkin, James M. G., additional, and Hodi, F. Stephen, additional

Published
2015
Full Text
View/download PDF

235. Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma.

Author

Long, Georgina V., primary, Stroyakovskiy, Daniil, additional, Gogas, Helen, additional, Levchenko, Evgeny, additional, De Braud, Filippo G., additional, Larkin, James M. G., additional, Garbe, Claus, additional, Jouary, Thomas, additional, Hauschild, Axel, additional, Grob, Jean Jacques, additional, Chiarion-Sileni, Vanna, additional, Lebbe, Celeste, additional, Mandalà, Mario, additional, Millward, Michael, additional, DeMarini, Douglas James, additional, Irani, Jhangir G, additional, Jin, Fan, additional, Swann, R. Suzanne, additional, Mookerjee, Bijoyesh, additional, and Flaherty, Keith, additional

Published
2015
Full Text
View/download PDF

236. A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.

Author

Di Giacomo, Anna Maria, primary, Annesi, Diego, additional, Ascierto, Paolo Antonio, additional, Calabrò, Luana, additional, Chiarion-Sileni, Vanna, additional, Danielli, Riccardo, additional, Del Vecchio, Michele, additional, Ferraresi, Virginia, additional, Ferrucci, Pier Francesco, additional, Fonsatti, Ester, additional, Guida, Michele, additional, Giannarelli, Diana, additional, Guidoboni, Massimo, additional, Mandalà, Mario, additional, Quaglino, Pietro, additional, Queirolo, Paola, additional, Maccalli, Cristina, additional, Parmiani, Giorgio, additional, and Maio, Michele, additional

Published
2015
Full Text
View/download PDF

238. Prognostic relevance of baseline neutrophils and derived neutrophil to lymphocyte ratio for ipilimumab-treated advanced melanoma patients.

Author

Ferrucci, Pier Francesco, primary, Giannarelli, Diana, additional, Gandini, Sara, additional, Cocorocchio, Emilia, additional, Del Vecchio, Michele, additional, Picasso, Virginia, additional, Pigozzo, Jacopo, additional, Di Giacomo, Anna Maria, additional, Simeone, Ester, additional, Chiarion-Sileni, Vanna, additional, Queirolo, Paola, additional, Maio, Michele, additional, Ascierto, Paolo Antonio, additional, and Martinoli, Chiara, additional

Published
2015
Full Text
View/download PDF

239. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma

Author

Schadendorf, Dirk, primary, Amonkar, Mayur M., additional, Stroyakovskiy, Daniil, additional, Levchenko, Evgeny, additional, Gogas, Helen, additional, de Braud, Filippo, additional, Grob, Jean-Jacques, additional, Bondarenko, Igor, additional, Garbe, Claus, additional, Lebbe, Celeste, additional, Larkin, James, additional, Chiarion-Sileni, Vanna, additional, Millward, Michael, additional, Arance, Ana, additional, Mandalà, Mario, additional, Flaherty, Keith T., additional, Nathan, Paul, additional, Ribas, Antoni, additional, Robert, Caroline, additional, Casey, Michelle, additional, DeMarini, Douglas J., additional, Irani, Jhangir G., additional, Aktan, Gursel, additional, and Long, Georgina V., additional

Published
2015
Full Text
View/download PDF

240. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

Author

Eggermont, Alexander M M, primary, Chiarion-Sileni, Vanna, additional, Grob, Jean-Jacques, additional, Dummer, Reinhard, additional, Wolchok, Jedd D, additional, Schmidt, Henrik, additional, Hamid, Omid, additional, Robert, Caroline, additional, Ascierto, Paolo A, additional, Richards, Jon M, additional, Lebbé, Céleste, additional, Ferraresi, Virginia, additional, Smylie, Michael, additional, Weber, Jeffrey S, additional, Maio, Michele, additional, Konto, Cyril, additional, Hoos, Axel, additional, de Pril, Veerle, additional, Gurunath, Ravichandra Karra, additional, de Schaetzen, Gaetan, additional, Suciu, Stefan, additional, and Testori, Alessandro, additional

Published
2015
Full Text
View/download PDF

242. Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

Author

Maio, Michele, primary, Grob, Jean-Jacques, additional, Aamdal, Steinar, additional, Bondarenko, Igor, additional, Robert, Caroline, additional, Thomas, Luc, additional, Garbe, Claus, additional, Chiarion-Sileni, Vanna, additional, Testori, Alessandro, additional, Chen, Tai-Tsang, additional, Tschaika, Marina, additional, and Wolchok, Jedd D., additional

Published
2015
Full Text
View/download PDF

243. Development and External Validation of a Prognostic Nomogram for Metastatic Uveal Melanoma

Author

Valpione, Sara, primary, Moser, Justin C., additional, Parrozzani, Raffaele, additional, Bazzi, Marco, additional, Mansfield, Aaron S., additional, Mocellin, Simone, additional, Pigozzo, Jacopo, additional, Midena, Edoardo, additional, Markovic, Svetomir N., additional, Aliberti, Camillo, additional, Campana, Luca G., additional, and Chiarion-Sileni, Vanna, additional

Published
2015
Full Text
View/download PDF

246. Genetic Features of Metachronous Esophageal Cancer Developed in Hodgkin’s Lymphoma or Breast Cancer Long-Term Survivors: An Exploratory Study

Author

Boldrin, Elisa, primary, Rumiato, Enrica, additional, Fassan, Matteo, additional, Cappellesso, Rocco, additional, Rugge, Massimo, additional, Chiarion-Sileni, Vanna, additional, Ruol, Alberto, additional, Alfieri, Rita, additional, Cagol, Matteo, additional, Castoro, Carlo, additional, Amadori, Alberto, additional, and Saggioro, Daniela, additional

Published
2015
Full Text
View/download PDF

247. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

Author

Robert, Caroline, primary, Long, Georgina V., additional, Brady, Benjamin, additional, Dutriaux, Caroline, additional, Maio, Michele, additional, Mortier, Laurent, additional, Hassel, Jessica C., additional, Rutkowski, Piotr, additional, McNeil, Catriona, additional, Kalinka-Warzocha, Ewa, additional, Savage, Kerry J., additional, Hernberg, Micaela M., additional, Lebbé, Celeste, additional, Charles, Julie, additional, Mihalcioiu, Catalin, additional, Chiarion-Sileni, Vanna, additional, Mauch, Cornelia, additional, Cognetti, Francesco, additional, Arance, Ana, additional, Schmidt, Henrik, additional, Schadendorf, Dirk, additional, Gogas, Helen, additional, Lundgren-Eriksson, Lotta, additional, Horak, Christine, additional, Sharkey, Brian, additional, Waxman, Ian M., additional, Atkinson, Victoria, additional, and Ascierto, Paolo A., additional

Published
2015
Full Text
View/download PDF

248. Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

Author

Long, Georgina V, primary, Atkinson, Victoria, additional, Ascierto, Paolo A, additional, Brady, Benjamin, additional, Dutriaux, Caroline, additional, Maio, Michele, additional, Mortier, Laurent, additional, Hassel, Jessica C., additional, Rutkowski, Piotr, additional, McNeil, Catriona, additional, Kalinka-Warzocha, Ewa, additional, Savage, Kerry J., additional, Hernberg, Micaela, additional, Lebbé, Celeste, additional, Charles, Julie, additional, Mihalcioiu, Catalin, additional, Chiarion-Sileni, Vanna, additional, Mauch, Cornelia, additional, Schmidt, Henrik, additional, Schadendorf, Dirk, additional, Gogas, Helen, additional, Horak, Christine, additional, Sharkey, Brian, additional, Waxman, Ian M., additional, and Robert, Caroline, additional

Published
2015
Full Text
View/download PDF

249. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Author

Robert, Caroline, primary, Karaszewska, Boguslawa, additional, Schachter, Jacob, additional, Rutkowski, Piotr, additional, Mackiewicz, Andrzej, additional, Stroiakovski, Daniil, additional, Lichinitser, Michael, additional, Dummer, Reinhard, additional, Grange, Florent, additional, Mortier, Laurent, additional, Chiarion-Sileni, Vanna, additional, Drucis, Kamil, additional, Krajsova, Ivana, additional, Hauschild, Axel, additional, Lorigan, Paul, additional, Wolter, Pascal, additional, Long, Georgina V., additional, Flaherty, Keith, additional, Nathan, Paul, additional, Ribas, Antoni, additional, Martin, Anne-Marie, additional, Sun, Peng, additional, Crist, Wendy, additional, Legos, Jeff, additional, Rubin, Stephen D., additional, Little, Shonda M., additional, and Schadendorf, Dirk, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results